Triazene compounds in the treatment of acute myeloid leukemia: A short review and a case report

L. Bonmassar, F. Marchesi, E. Pascale, O. Franzese, G. P. Margison, A. Bianchi, S. D'Atri, S. Bernardini, D. Lattuada, E. Bonmassar, A. Aquino

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Acute myeloid leukemia (AML) is a highly lethal disease, especially in old patients. Chemoresistance and the absence of host immune responses against autochthonous malignancy play a major role in the poor prognosis of AML. The triazene compounds Dacarbazine and Temozolomide are monofunctional alkylators that donate methyl groups to many sites in DNA, including the O6-position of guanine producing O6-methylguanine (O6-MeG). If not repaired, O6- MeG frequently mispairs with thymine during DNA duplication. O6-MeG:T mismatches can be recognized by the mismatch repair (MMR) system which activates a cascade of molecular events leading to cell cycle arrest and cell death. If MMR is defective, cells continue to divide and GC × AT transition mutations occur. In preclinical models, such mutations can lead to the appearance of abnormal proteins containing non-self peptides ('chemical xenogenization' CX) that can be recognized by host cell-mediated immunity. Repair of O6-MeG is achieved by the DNA repair protein, O6- methylguanine-DNA methyltransferase (MGMT), which removes the methyl adduct in an autoinactivating stoichiometric reaction. High MGMT levels attenuate the pharmacodynamic effects of triazenes. In the last few years, triazenes, alone or with MGMT inhibitors, have been tested in AML. In view of their potential activity as CX inducers, triazenes could offer the additional advantage of host anti-leukemia immune responses. The present paper describes several studies of leukemia treatment with triazenes and a case of acute refractory leukemia with massive skin infiltration by malignant cells. Treatment with Temozolomide and Lomeguatrib, a potent MGMT inhibitor, produced a huge, although transient, blastolysis and complete disappearance of all skin lesions.

Original languageEnglish
Pages (from-to)2389-2401
Number of pages13
JournalCurrent Medicinal Chemistry
Volume20
Issue number19
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Triazenes
Acute Myeloid Leukemia
temozolomide
Methyltransferases
DNA
Repair
Leukemia
DNA Mismatch Repair
Therapeutics
Skin
Dacarbazine
Mutation
Pharmacodynamics
Thymine
Alkylating Agents
Guanine
Cell Cycle Checkpoints
Cellular Immunity
DNA Repair
Cell death

Keywords

  • Acute myeloid leukaemia
  • Chemical xenogenization (CX)
  • Lomeguatrib
  • MGMT inhibitors
  • O6-Methylguanine-DNA methyltransferase (MGMT)
  • Temozolomide (TMZ)
  • Triazene compounds

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Bonmassar, L., Marchesi, F., Pascale, E., Franzese, O., Margison, G. P., Bianchi, A., ... Aquino, A. (2013). Triazene compounds in the treatment of acute myeloid leukemia: A short review and a case report. Current Medicinal Chemistry, 20(19), 2389-2401. https://doi.org/10.2174/0929867311320190001

Triazene compounds in the treatment of acute myeloid leukemia : A short review and a case report. / Bonmassar, L.; Marchesi, F.; Pascale, E.; Franzese, O.; Margison, G. P.; Bianchi, A.; D'Atri, S.; Bernardini, S.; Lattuada, D.; Bonmassar, E.; Aquino, A.

In: Current Medicinal Chemistry, Vol. 20, No. 19, 06.2013, p. 2389-2401.

Research output: Contribution to journalArticle

Bonmassar, L, Marchesi, F, Pascale, E, Franzese, O, Margison, GP, Bianchi, A, D'Atri, S, Bernardini, S, Lattuada, D, Bonmassar, E & Aquino, A 2013, 'Triazene compounds in the treatment of acute myeloid leukemia: A short review and a case report', Current Medicinal Chemistry, vol. 20, no. 19, pp. 2389-2401. https://doi.org/10.2174/0929867311320190001
Bonmassar, L. ; Marchesi, F. ; Pascale, E. ; Franzese, O. ; Margison, G. P. ; Bianchi, A. ; D'Atri, S. ; Bernardini, S. ; Lattuada, D. ; Bonmassar, E. ; Aquino, A. / Triazene compounds in the treatment of acute myeloid leukemia : A short review and a case report. In: Current Medicinal Chemistry. 2013 ; Vol. 20, No. 19. pp. 2389-2401.
@article{2960a3acbae749d3b0d935f164af02f5,
title = "Triazene compounds in the treatment of acute myeloid leukemia: A short review and a case report",
abstract = "Acute myeloid leukemia (AML) is a highly lethal disease, especially in old patients. Chemoresistance and the absence of host immune responses against autochthonous malignancy play a major role in the poor prognosis of AML. The triazene compounds Dacarbazine and Temozolomide are monofunctional alkylators that donate methyl groups to many sites in DNA, including the O6-position of guanine producing O6-methylguanine (O6-MeG). If not repaired, O6- MeG frequently mispairs with thymine during DNA duplication. O6-MeG:T mismatches can be recognized by the mismatch repair (MMR) system which activates a cascade of molecular events leading to cell cycle arrest and cell death. If MMR is defective, cells continue to divide and GC × AT transition mutations occur. In preclinical models, such mutations can lead to the appearance of abnormal proteins containing non-self peptides ('chemical xenogenization' CX) that can be recognized by host cell-mediated immunity. Repair of O6-MeG is achieved by the DNA repair protein, O6- methylguanine-DNA methyltransferase (MGMT), which removes the methyl adduct in an autoinactivating stoichiometric reaction. High MGMT levels attenuate the pharmacodynamic effects of triazenes. In the last few years, triazenes, alone or with MGMT inhibitors, have been tested in AML. In view of their potential activity as CX inducers, triazenes could offer the additional advantage of host anti-leukemia immune responses. The present paper describes several studies of leukemia treatment with triazenes and a case of acute refractory leukemia with massive skin infiltration by malignant cells. Treatment with Temozolomide and Lomeguatrib, a potent MGMT inhibitor, produced a huge, although transient, blastolysis and complete disappearance of all skin lesions.",
keywords = "Acute myeloid leukaemia, Chemical xenogenization (CX), Lomeguatrib, MGMT inhibitors, O6-Methylguanine-DNA methyltransferase (MGMT), Temozolomide (TMZ), Triazene compounds",
author = "L. Bonmassar and F. Marchesi and E. Pascale and O. Franzese and Margison, {G. P.} and A. Bianchi and S. D'Atri and S. Bernardini and D. Lattuada and E. Bonmassar and A. Aquino",
year = "2013",
month = "6",
doi = "10.2174/0929867311320190001",
language = "English",
volume = "20",
pages = "2389--2401",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "19",

}

TY - JOUR

T1 - Triazene compounds in the treatment of acute myeloid leukemia

T2 - A short review and a case report

AU - Bonmassar, L.

AU - Marchesi, F.

AU - Pascale, E.

AU - Franzese, O.

AU - Margison, G. P.

AU - Bianchi, A.

AU - D'Atri, S.

AU - Bernardini, S.

AU - Lattuada, D.

AU - Bonmassar, E.

AU - Aquino, A.

PY - 2013/6

Y1 - 2013/6

N2 - Acute myeloid leukemia (AML) is a highly lethal disease, especially in old patients. Chemoresistance and the absence of host immune responses against autochthonous malignancy play a major role in the poor prognosis of AML. The triazene compounds Dacarbazine and Temozolomide are monofunctional alkylators that donate methyl groups to many sites in DNA, including the O6-position of guanine producing O6-methylguanine (O6-MeG). If not repaired, O6- MeG frequently mispairs with thymine during DNA duplication. O6-MeG:T mismatches can be recognized by the mismatch repair (MMR) system which activates a cascade of molecular events leading to cell cycle arrest and cell death. If MMR is defective, cells continue to divide and GC × AT transition mutations occur. In preclinical models, such mutations can lead to the appearance of abnormal proteins containing non-self peptides ('chemical xenogenization' CX) that can be recognized by host cell-mediated immunity. Repair of O6-MeG is achieved by the DNA repair protein, O6- methylguanine-DNA methyltransferase (MGMT), which removes the methyl adduct in an autoinactivating stoichiometric reaction. High MGMT levels attenuate the pharmacodynamic effects of triazenes. In the last few years, triazenes, alone or with MGMT inhibitors, have been tested in AML. In view of their potential activity as CX inducers, triazenes could offer the additional advantage of host anti-leukemia immune responses. The present paper describes several studies of leukemia treatment with triazenes and a case of acute refractory leukemia with massive skin infiltration by malignant cells. Treatment with Temozolomide and Lomeguatrib, a potent MGMT inhibitor, produced a huge, although transient, blastolysis and complete disappearance of all skin lesions.

AB - Acute myeloid leukemia (AML) is a highly lethal disease, especially in old patients. Chemoresistance and the absence of host immune responses against autochthonous malignancy play a major role in the poor prognosis of AML. The triazene compounds Dacarbazine and Temozolomide are monofunctional alkylators that donate methyl groups to many sites in DNA, including the O6-position of guanine producing O6-methylguanine (O6-MeG). If not repaired, O6- MeG frequently mispairs with thymine during DNA duplication. O6-MeG:T mismatches can be recognized by the mismatch repair (MMR) system which activates a cascade of molecular events leading to cell cycle arrest and cell death. If MMR is defective, cells continue to divide and GC × AT transition mutations occur. In preclinical models, such mutations can lead to the appearance of abnormal proteins containing non-self peptides ('chemical xenogenization' CX) that can be recognized by host cell-mediated immunity. Repair of O6-MeG is achieved by the DNA repair protein, O6- methylguanine-DNA methyltransferase (MGMT), which removes the methyl adduct in an autoinactivating stoichiometric reaction. High MGMT levels attenuate the pharmacodynamic effects of triazenes. In the last few years, triazenes, alone or with MGMT inhibitors, have been tested in AML. In view of their potential activity as CX inducers, triazenes could offer the additional advantage of host anti-leukemia immune responses. The present paper describes several studies of leukemia treatment with triazenes and a case of acute refractory leukemia with massive skin infiltration by malignant cells. Treatment with Temozolomide and Lomeguatrib, a potent MGMT inhibitor, produced a huge, although transient, blastolysis and complete disappearance of all skin lesions.

KW - Acute myeloid leukaemia

KW - Chemical xenogenization (CX)

KW - Lomeguatrib

KW - MGMT inhibitors

KW - O6-Methylguanine-DNA methyltransferase (MGMT)

KW - Temozolomide (TMZ)

KW - Triazene compounds

UR - http://www.scopus.com/inward/record.url?scp=84877962528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877962528&partnerID=8YFLogxK

U2 - 10.2174/0929867311320190001

DO - 10.2174/0929867311320190001

M3 - Article

C2 - 23521681

AN - SCOPUS:84877962528

VL - 20

SP - 2389

EP - 2401

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 19

ER -